Holen Sie sich die Stockscreener-App
35.96
0.70%
-0.29
Handel nachbörslich:
35.96
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$36.25
Offen:
$35.27
24-Stunden-Volumen:
1.22M
Relative Volume:
0.51
Marktkapitalisierung:
$4.97B
Einnahmen:
$181.74M
Nettoeinkommen (Verlust:
$-143.97M
KGV:
-25.87
EPS:
-1.39
Netto-Cashflow:
$9.60M
1W Leistung:
-1.49%
1M Leistung:
+21.11%
6M Leistung:
+191.69%
1J Leistung:
+85.92%
1-Tages-Spanne:
$34.61
$36.41
1-Wochen-Bereich:
$34.61
$37.30
52-Wochen-Spanne:
$9.57
$39.42
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Firmenname
Arrowhead Pharmaceuticals Inc
Sektor
Branche
Telefon
626-696-4702
Adresse
177 E COLORADO BLVD, PASADENA, CA
Vergleichen Sie ARWR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
35.96 | 5.01B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-05 | Eingeleitet | Goldman | Neutral |
| 2023-12-04 | Eingeleitet | BofA Securities | Buy |
| 2023-09-19 | Eingeleitet | Citigroup | Neutral |
| 2023-07-21 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-12 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-12 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-19 | Eingeleitet | Citigroup | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Eingeleitet | Goldman | Neutral |
| 2020-01-21 | Eingeleitet | SVB Leerink | Underperform |
| 2019-12-13 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-29 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-27 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-25 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-10-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-09-07 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-08-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Applying Wyckoff theory to Arrowhead Pharmaceuticals Inc. stockQuarterly Portfolio Report & Target Return Focused Picks - newser.com
What Fibonacci levels say about Arrowhead Pharmaceuticals Inc. reboundJuly 2025 Action & Community Consensus Picks - newser.com
What to expect from Arrowhead Pharmaceuticals Inc. in the next 30 daysPortfolio Value Report & Intraday High Probability Setup Alerts - newser.com
How buybacks impact Arrowhead Pharmaceuticals Inc. stock valueTrade Analysis Summary & Verified Stock Trade Ideas - newser.com
Is Arrowhead Pharmaceuticals Inc. stock attractive for growth ETFs2025 Retail Activity & Technical Buy Zone Confirmations - newser.com
Advanced analytics toolkit walkthrough for Arrowhead Pharmaceuticals Inc.Quarterly Market Review & Long-Term Growth Portfolio Plans - newser.com
Sector ETF performance correlation with Arrowhead Pharmaceuticals Inc.2025 Risk Factors & Low Risk High Reward Ideas - newser.com
Is Arrowhead Pharmaceuticals Inc. showing signs of accumulationOil Prices & Verified Swing Trading Watchlist - newser.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Arrowhead Pharmaceuticals Inc a good long term investmentSector Performance Review & Free Double Digit Growth Tips - earlytimes.in
Arrowhead Pharmaceuticals Inc HDP1 Stock Analysis and ForecastMACD Histogram Signals & Budget Friendly Capital Growth - earlytimes.in
Short interest data insights for Arrowhead Pharmaceuticals Inc.July 2025 Snapshot & Free Real-Time Market Sentiment Alerts - newser.com
Arrowhead Pharmaceuticals Inc. stock chart pattern explainedEarnings Recap Summary & Community Supported Trade Ideas - newser.com
Pinion Investment Advisors LLC Has $1.19 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Will Arrowhead Pharmaceuticals Inc. see short term momentum2025 Price Targets & Daily Market Momentum Tracking - newser.com
Has Arrowhead Pharmaceuticals Inc. found a price floorJuly 2025 Fed Impact & Low Drawdown Investment Strategies - newser.com
Can Arrowhead Pharmaceuticals Inc. stock deliver surprise earnings beatJuly 2025 EndofMonth & Real-Time Sentiment Analysis - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals (ARWR): Valuation Insights Following First-in-Class RNAi Therapy Trial Application - Sahm
Is Arrowhead Pharmaceuticals Inc. still worth holding after the dipM&A Rumor & Consistent Growth Stock Picks - newser.com
What technical models suggest about Arrowhead Pharmaceuticals Inc.’s comebackM&A Rumor & Low Volatility Stock Suggestions - newser.com
Arrowhead Pharmaceuticals (ARWR) Is Up 5.9% After Filing for First Dual-Gene RNAi Therapy Trial – Has the Long-Term Thesis Shifted? - Sahm
Arrowhead Pharma stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Buy Rating at HC Wainwright - MarketBeat
RBC Raises Price Target on Arrowhead Pharmaceuticals to $45 From $38, Keeps Outperform, Speculative Risk - MarketScreener
HC Wainwright & Co. Reiterates Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - Nasdaq
Arrowhead Pharma (ARWR) Analyst Rating Update: HC Wainwright & C - GuruFocus
Arrowhead Pharmaceuticals Hits New 52-Week High of $39.42 - Markets Mojo
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - BioSpace
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNA - PharmiWeb.com
Arrowhead Pharmaceuticals Hits New 52-Week High of $36.24 - Markets Mojo
RNAi: The Benefits Of Shooting The Messenger - Seeking Alpha
Arrowhead Pharmaceuticals And Wave Life Sciences: RNAi Is Getting Into Obesity (NASDAQ:WVE) - Seeking Alpha
Arrowhead Pharmaceuticals files CTA for investigational Aro-Dimer-PA - MarketScreener
Arrowhead files for approval of dual-target RNAi therapy for heart disease - Investing.com Nigeria
What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You - simplywall.st
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 12-Month HighStill a Buy? - MarketBeat
Will Arrowhead Pharmaceuticals Inc. stock outperform Dow Jones indexJuly 2025 Price Swings & Verified Entry Point Signals - newser.com
Tools to monitor Arrowhead Pharmaceuticals Inc. recovery probabilityEarnings Miss & AI Driven Stock Price Forecasts - newser.com
Insider Sell: James Hamilton Sells 20,000 Shares of Arrowhead Ph - GuruFocus
Future of RNAi Therapeutics: Small Interfering RNAs, - openPR.com
Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):